This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Johnson & Johnson's (JNJ - Get Report) shares sank 1.2% to $66.40 despite better-than-expected fourth-quarter earnings.

Excluding certain charges, the company earned 81 cents a share, 2 cents higher than analysts' estimates. Revenue reached $13.68 billion, up from $12.61 billion last year and in line with analysts' estimates.

However, the company said its acquisition of Pfizer's (PFE - Get Report) consumer health care group won't add to its earnings until 2009. Earnings per share in 2007 are expected to take a 12-cent hit, and 2008 earnings should be reduced by 3 cents, excluding certain items.

Shares of Novavax (NVAX - Get Report) gained 4.4% to $4.27 after the company reported additional data on its pandemic flu vaccine after the close of trading Monday.

Valeant Pharmaceuticals' (VRX - Get Report) shares gained 3.2% to $17.66 after the company restated its third-quarter earnings to reflect stock option expense. Valeant and said it recorded a profit of $13.7 million, or 14 cents a share. The company lost $2.7 million, or 3 cents a share, in the third quarter a year ago.

NitroMed (NTMD) gained 10.5% to $2.94 after the drugmaker said it named a new chief executive officer and chief financial officer. Former Millennium Pharmaceuticals (MLNM) executive vice president Kenneth Bate will serve as the company's CEO, and business consultant James Ham will be CFO.

Among other health stock winners Tuesday were Bayer (BAY), up 1.9% to $57.20; Caraco Pharmaceutical (CPD), gaining 2.1% to $13.18; Noven Pharmaceuticals (NOVN), rising 2.7% to $26.33; and Neurocrine Biosciences (NBIX), jumping 6.7% to $13.82.

Among the losers were Pfizer, whose shares fell 2.5% to $26.27; Genentech (DNA), off 1.1% to $87.91; Amgen (AMGN), down 1.4% to $74.80; Biogen Idec (BIIB), 1.9% lower to $49.24; and ImClone Systems (IMCL), sinking 3.7% to $28.07.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
JNJ $101.12 0.04%
NVAX $8.56 -0.23%
PFE $35.11 -0.45%
VRX $206.08 -2.10%
AAPL $132.68 1.80%

Markets

DOW 18,134.66 +54.52 0.30%
S&P 500 2,121.30 +3.61 0.17%
NASDAQ 5,103.0280 +10.9430 0.21%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs